{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T18:47:56Z","timestamp":1763837276611,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bmc.2021.116239","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T04:31:13Z","timestamp":1622176273000},"page":"116239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses"],"prefix":"10.1016","volume":"42","author":[{"given":"Zhipeng","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongxia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-953X","authenticated-orcid":false,"given":"Dongwei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasulu","family":"Cherukupalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"De Clercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Pannecouque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2021.116239_b0005","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/med.20241","article-title":"HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design","volume":"33","author":"Zhan","year":"2013","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2021.116239_b0010","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116239_b0015","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1021\/acsmedchemlett.8b00054","article-title":"Further exploring solvent-exposed tolerant regions of allosteric binding pocket for novel HIV-1 NNRTIs discovery","volume":"9","author":"Kang","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2021.116239_b0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","article-title":"Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments","volume":"98","author":"Men\u00e9ndez-Arias","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmc.2021.116239_b0025","first-page":"215","article-title":"International AIDS society-USA drug resistance mutations group. Drug resistance mutations in HIV-1","volume":"11","author":"Johnson","year":"2003","journal-title":"Top HIV Med"},{"key":"10.1016\/j.bmc.2021.116239_b0030","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1021\/jm040127p","article-title":"From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase","volume":"48","author":"De Corte","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116239_b0035","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.apsb.2015.09.001","article-title":"An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964\u20132014","volume":"5","author":"De Clercq","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2021.116239_b0040","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2174\/09298673113206660298","article-title":"Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009\u20132013 update","volume":"21","author":"Song","year":"2014","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2021.116239_b0045","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1517\/13543776.2014.964685","article-title":"Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011\u20132014)","volume":"24","author":"Li","year":"2014","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmc.2021.116239_b0050","first-page":"132","article-title":"2017 update of the drug resistance mutations in HIV-1","volume":"24","author":"Wensing","year":"2016","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.bmc.2021.116239_b0055","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","article-title":"Anti-HIV drug discovery and development: current innovations and future trends","volume":"59","author":"Zhan","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116239_b0060","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.apsb.2019.08.009","article-title":"Synthesis and biological evaluation of a series of 2-(((5-akly\/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2021.116239_b0065","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.apsb.2019.08.013","article-title":"Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs","volume":"10","author":"Kang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2021.116239_b0070","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1021\/jm1002233","article-title":"Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design","volume":"53","author":"Lansdon","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116239_b0075","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1073\/pnas.0711209105","article-title":"High-resolution structures of HIV-1 reverse transcriptase\/TMC278 complexes: strategic flexibility explains potency against resistance mutations","volume":"105","author":"Das","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmc.2021.116239_b0080","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.cclet.2020.03.028","article-title":"New techniques and strategies in drug discovery","volume":"31","author":"Du","year":"2020","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.bmc.2021.116239_b0085","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1021\/jm030558s","volume":"47","author":"Das","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116239_b0090","doi-asserted-by":"crossref","first-page":"16705","DOI":"10.1021\/ja408917n","article-title":"Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group","volume":"135","author":"Lee","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2021.116239_b0095","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.apsb.2019.09.007","article-title":"Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"10","author":"Jin","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2021.116239_b0100","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1039\/C7OB02828H","article-title":"Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored \u201chydrophobic channel\u201d","volume":"16","author":"Zhou","year":"2018","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmc.2021.116239_b0105","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1039\/C9OB00032A","article-title":"Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus","volume":"17","author":"Zhou","year":"2019","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmc.2021.116239_b0110","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1016\/j.bmc.2015.09.020","article-title":"A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: design, synthesis and anti-HIV activities","volume":"23","author":"Gu","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2021.116239_b0115","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2016.05.054","article-title":"Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket","volume":"121","author":"Chen","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2021.116239_b0120","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1021\/acs.jmedchem.8b01729","volume":"62","author":"Huang","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116239_b0125","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/jps.22242","article-title":"Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: etravirine","volume":"100","author":"Weuts","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmc.2021.116239_b0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1359-6446(99)01451-8","article-title":"Computational methods for the prediction of \u2018drug-likeness\u2019","volume":"5","author":"Clark","year":"2000","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2021.116239_b0135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40262-019-00830-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of etravirine: an updated review","volume":"59","author":"Havens","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bmc.2021.116239_b0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13321-018-0283-x","article-title":"ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database","volume":"10","author":"Dong","year":"2018","journal-title":"J Cheminform"},{"key":"10.1016\/j.bmc.2021.116239_b0145","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0166-0934(88)90134-6","article-title":"Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds","volume":"20","author":"Pauwels","year":"1988","journal-title":"J Virol Methods"},{"key":"10.1016\/j.bmc.2021.116239_b0150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nprot.2007.517","article-title":"Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later","volume":"3","author":"Pannecouque","year":"2008","journal-title":"Nat Protoc"},{"key":"10.1016\/j.bmc.2021.116239_b0155","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.bmc.2009.07.004","article-title":"Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: synthesis and preliminary SAR studies","volume":"17","author":"Zhan","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2021.116239_b0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0166-0934(93)90054-U","article-title":"Poly A-linked colorimetric microtiter plate assay for HIV reverse transcriptase","volume":"44","author":"Suzuki","year":"1993","journal-title":"J Virol Methods"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621002479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621002479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:12:46Z","timestamp":1760836366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089621002479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":32,"alternative-id":["S0968089621002479"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116239","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116239"}}